Nichtsteroidale Antirheumatika bei rheumatischen Erkrankungen – Was spricht dagegen?

Trotz des unbestrittenen Nutzens in der Ko-Analgesie nahezu sämtlicher rheumatischer Erkrankungen birgt der flächenhafte und vor allem unkritische Einsatz von nichtsteroidalen Antiphlogistika (NSAID; non-steroidal antiinflammatory drugs) erhebliche Gefahren. Besonders kardiale, gastrointestinale und renale Nebenwirkungen sind in der Praxis höchst relevant. Der verschreibende Arzt muss außerdem beachten, dass eine Vielzahl der älteren Medikamente (z. B. Ibuprofen) frei verkäuflich ist.

• Literatur

• 1 da Costa BR, Reichenbach S, Keller N. et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016; 387: 2093-2105
• 2 Sieper J, Listing J, Poddubnyy D. et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiografic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 2016; 75: 1438-1443
• 3 Nissen SE, Yeomans ND, Solomon DH. et al. PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med 2016; 375: 2519-2529
• 4 Alvarez PA, Putney D, Ogunti R. et al. Prevalence of in-hospital nonsteroidal antiinflammatory drug exposure in patients with a primary diagnosis of heart failure. Cardiovasc Ther 2017 35.
• 5 Shukla A, Rai MK, Prasad N. et al. Short-Term Non-Steroid Anti-Inflammatory Drug Use in Spondyloarthritis Patients Induces Subclinical Acute Kidney Injury: Biomarkers Study. Nephron 2017; 135: 277-286
• 6 Ungprasert P, Cheungpasitporn W, Crowson CS. et al. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med 2015; 26: 285-291
• 7 Weiner SM, Bergner R. Dosage and toxicity of antirheumatic drugs in renal insufficiency. Z Rheumatol 2015; 74: 300-309
• 8 Chan FKL, Ching JYL, Tse YK. et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet 2017; 389: 2375-2382
• 9 Zhang S, Zhang Y, Liu P. et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol 2016; 35: 151-158